Recommended

AstraZeneca boosts production capacity at Texas facility following $445m investment
ESMO 2025: Keytruda immunotherapy shows promise in skin cancer
AstraZeneca research illustrates potential of autonomous UVC disinfection in pharma cleanrooms
Webinar: Radiopharmaceuticals’ time-to-result challenge
Ipsen €1bn ImCheck Therapeutics acquisition deal
Phase III data for next-gen green inhaler push GSK closer to Net Zero targets
Lilly progresses Incyte’s JAK inhibitor in major study
news

FDA grants Orphan Drug Designation to Imfinzi for SCLC

5
SHARES

The FDA has announced Orphan Drug Designation for Imfinzi (durvalumab) to treat small cell lung cancer in combination with other therapies.

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Imfinzi (durvalumab), a PD-L1 inhibitor for the treatment of patients with extensive-stage small cell lung cancer (SCLC).

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The drug is a monoclonal antibody that binds to PD-L1 and blocks the interaction between PD-L1 with PD-1 and CD80, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses. 

The AstraZeneca Phase III CASPIAN study found positive results for the medication in June. The trial saw the treatment meet its primary endpoints when combined with the standard-of-care medicine, etoposide and platinum-based chemotherapy.

It is the first study to offer the flexibility of combining immunotherapy with different platinum-based regimens in small lung cancer.

José Baselga, Executive Vice President, R&D Oncology, said the company is “eager to expand treatment options for patients facing such a devastating diagnosis and look forward to working with regulatory authorities to bring forward new options as soon as possible.”

Imfinzi is currently approved for unresectable, stage III non-small cell lung cancer (NSCLC) in the US. The company is evaluating the drug in several late-stage programmes for treating stage IV NSCLC. 

The drug is also being tested in the Phase III ADRIATIC assessment following a concurrent chemoradiation therapy for the limited-stage SCLC.

Share via
Share via